As a whole, these data demonstrated that a VEGF165/SOX2/SRSF2 network controls VEGFR1 pre-mRNA splicing towards sVEGFR1-i13 expression in lung cancer cells treated with anti-angiogenic therapies (Fig. 6). The gene discussed is FLT1; the disease is lung carcinoma.